Laboratorios Rovi (ROVI) Q1 net profit nearly halves, revenue forecast cut
Laboratorios Rovi announced a significant 48% reduction in its net profit for the first quarter of 2026, which settled at €9.4 million, down from €18.1 million in the same period last year. Concurrently, the Spanish pharmaceutical firm revised its full-year 2026 operating revenue growth forecast downwards, now anticipating a low-to-mid single-digit increase compared to 2025. This adjustment marks a more conservative outlook than previously communicated.
The decline in net profit is largely attributed to a notable increase in operating expenses, particularly within research and development, which contributed to a 33% fall in EBITDA. The revised revenue projections stem primarily from lower expectations regarding a pre-filled syringe manufacturing agreement with a global pharmaceutical company. This recalibration follows a delay in the commencement of routine manufacturing operations and heightened uncertainty surrounding anticipated demand.
The announcement, made on May 12, has extended the downward trajectory of ROVI shares. On May 13, Laboratorios Rovi is trading at €59.85, marking a 2.0% decrease. This current price compares to a previous close of €61.10 on May 12 and continues the losses observed since the Q1 results and guidance cut began impacting the stock in prior sessions.
Why a Syringe Manufacturing Delay is Weighing on Rovi
Laboratorios Rovi is a Spanish pharmaceutical company that operates on two main fronts: it researches, develops, and sells its own patented and generic medicines, and it also acts as a contract manufacturer for other major global pharmaceutical firms. This second part of their business involves specialised services, such as producing pre-filled syringes, which generates significant revenue.
Today's share price movement for Rovi is primarily driven by a downward revision of its 2026 operating revenue growth forecasts. This moderation in outlook stems largely from a delay in the routine manufacturing start-up for a crucial pre-filled syringe agreement with a global pharmaceutical company, alongside increased uncertainty about future demand for this product. This factor, coupled with a notable rise in operating expenses, particularly in research and development, contributed to a significant 48% drop in its first-quarter net profit, which stood at €9.4 million.
As a direct result of this news, Laboratorios Rovi shares are currently trading at €59.85, marking a 2.0% decrease from yesterday's closing price of €61.10.
Imagine a bespoke furniture maker who has secured a large contract to supply custom pieces, but then announces that the delivery of a key component will be delayed, potentially affecting the final order size. While their craftsmanship remains excellent, the uncertainty about when the expected income will arrive, and in what quantity, forces investors to adjust their valuation of the company.
![Laboratorios Rovi[es] logo](https://images.financialmodelingprep.com/symbol/ROVI.MC.png)
Laboratorios Rovi[es]
Laboratorios Farmaceuticos Rovi, S.A. (ROVI) is a Spanish pharmaceutical firm engaged in the research, development, production, and commercialisation of a diverse range of pharmaceutical products. Its portfolio includes treatments for venous thromboembolic disease (Hibor, Becat), heart failure (Neparvis), hypercholesterolemia (Absorcol, Vytorin, Orvatez), chronic obstructive pulmonary diseases (Hirobriz Breezhaler, Ulunar Breezhaler), benign prostatic hyperplasia (Volutsa), and ADHD (Medikinet, Medicebrán). ROVI also markets hospital products for imaging diagnostics, such as contrast agents (Iomeron, Iopamiro, Multihance, Prohance, Sonovue) and contrast injection systems. Beyond its proprietary offerings, the company provides contract manufacturing services for various pharmaceutical forms and distributes licensed products from other laboratories. ROVI serves a broad client base including wholesalers, medical professionals, and patients across Spain, the European Union, OECD countries, and internationally. Founded in 1946, it is headquartered in Madrid, Spain.